Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pentostatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA known ✓ | P00813 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | TK2 | O00142 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentostatin SCHEMBL724965 | 0.90 | LMNA (0.66) | TK1LMNASMN1; SMN2CYP1A2CYP3A4 | |
| Pentostatin SCHEMBL14190839 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A | |
| Pentostatin SCHEMBL21133143 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A | |
| Pentostatin SCHEMBL12202591 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A | |
| Pentostatin SCHEMBL7790216 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A | |
| Pentostatin SCHEMBL2353499 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A | |
| Pentostatin SCHEMBL2819465 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A | |
| Pentostatin SCHEMBL14105501 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A | |
| Pentostatin SCHEMBL7715689 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A | |
| Pentostatin SCHEMBL18402543 | 0.86 | ADA (0.57) | LMNASMN1; SMN2ADAADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328832-A1 | FUCOSIDASE INHIBITORS | Horizon Orphan LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017019925-A1 | FUCOSIDASE INHIBITORS | RAPTOR PHARMACEUTICALS INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-2528613-A1 | METHOD FOR TREATING LIVER DISORDERS WITH RECEPTOR ASSOCIATED PROTEIN ( IRP) PEPTIDE-FUCOSIDASE INHIBITOR CONJUGATES | Raptor Discoveries Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011094536-A1 | METHOD FOR TREATING LIVER DISORDERS WITH RECEPTOR ASSOCIATED PROTEIN ( IRP) PEPTIDE-FUCOSIDASE INHIBITOR CONJUGATES | RAPTOR PHARMACEUTICALLS INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| EP-2132224-A1 | CYCLIC RECEPTOR-ASSOCIATED PROTEIN (RAP) PEPTIDES | Raptor Pharmaceutical Inc (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116171-A1 | CYCLIC RECEPTOR-ASSOCIATED PROTEIN (RAP) PEPTIDES | RAPTOR PHARMACEUTICAL INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| EP-1919505-A2 | SINGLE DOSE USE OF CD20-SPECIFIC BINDING MOLECULES | Trubion Pharmaceuticals, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007014238-A2 | SINGLE DOSE USE OF CD20-SPECIFIC BINDING MOLECULES | TRUBION PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| EP-1667684-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS Corporation (US) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005027907-A1 | USE OF CHK1 INHIBITORS TO CONTROL CELL PROLIFERATION | ICOS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |